Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats pathological hypersecretory conditions. ANDA 217400, held by Msn. Famotidine.
As of Nov 15, 2026, ANDA 217400 (Famotidine), held by Msn, was first approved by FDA on Aug 6, 2024, with 0 approved supplements and 0 published complete response letters.
First approved: Aug 6, 2024
Review: Standard
Supplements approved: 0
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of:
reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated: In adult and pediatric patients 40 kg and greater for the treatment of:
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
